Roxane's Cafcit Approval Based On Post-Hoc Analysis Of Phase III Trial
Executive Summary
FDA approved Roxane's Cafcit (caffeine citrate) on Sept. 21 based on a literature review and a post-hoc analysis of secondary endpoints from a Phase III trial.
You may also be interested in...
FDA Developing Predictive Database To Help Screen Rx Imports
FDA is working with the New Mexico State University Physical Sciences Lab to develop a predictive database to help allocate resources for intercepting prescription drug imports
FDA Developing Predictive Database To Help Screen Rx Imports
FDA is working with the New Mexico State University Physical Sciences Lab to develop a predictive database to help allocate resources for intercepting prescription drug imports
I.V. Product Diluent Compatibility Tests May Be Required For FDA Approval
FDA is considering requiring NDAs for I.V. drugs to include a battery of compatibility tests with the six most common diluents.